Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo approval

This article was originally published in The Tan Sheet

Executive Summary

Generics firm receives ANDA approval Sept. 23 for 100 mg/5 mL ibuprofen oral suspension, equivalent to McNeil's Children's Motrin. Perrigo and Alpharma recently settled FTC antitrust charges over a 1998 marketing agreement under which Perrigo marketed a Children's Motrin equivalent during Alpharma's exclusivity period (1"The Tan Sheet" Aug. 16, 2004, p. 3)...

You may also be interested in...

Rx Or OTC Statins May Be Springboard For Perrigo Generics Unit

Perrigo is looking into developing its own line of private label statin drugs

FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals

The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny

Mylan Symbicort Trial Looms As Company Eyes First US Generic

A trial will begin next month in Mylan’s bid to overcome patents shielding AstraZeneca’s Symbicort respiratory brand in the US. With rival Teva having previously settled ANDA action, Mylan is in the driving seat for a first substitutable generic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts